GlassScriptPhysician profile
Abhilasha Singh
NPI 1851741342
$1,588.86
in general payments reported to CMS, 2019-2025
24 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.19 · 2022: $107 · 2023: $626 · 2024: $454 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,371 · Education: $70.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.84 |
| Education | $70.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $287.91 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Beta Bionics, INC. | $171.36 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $143.58 | 2023-2024 | Tymlos |
| Corcept Therapeutics | $139.19 | 2021-2024 | Korlym |
| Lilly USA, LLC | $125.79 | 2022-2024 | Jardiance, Mounjaro |
| Medtronic, INC. | $83.98 | 2022-2025 | Minimed 780g |
| Abbott Laboratories | $68.01 | 2023-2024 | Freestyle Libre 3 |
| Insulet Corporation | $66.47 | 2022-2024 | Omnipod |
| Abbvie INC. | $58.76 | 2023 | Synthroid |
| Tandem Diabetes Care, INC. | $57.06 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $51.45 | 2023-2024 | Dexcom G6 Transmitter |
| Octapharma USA, INC. | $45.43 | 2025 | Panzyga |
| Sanofi-Aventis U.S. LLC | $45.40 | 2021-2023 | |
| Astellas Pharma US INC | $37.87 | 2025 | Veozah |
| Novo Nordisk INC | $32.98 | 2023-2024 | Wegovy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $27.83 | 2025 | Twiist |
| Amgen INC. | $27.34 | 2023-2025 | Repatha, Prolia, Evenity |
| Ascensia Diabetes Care US INC. | $20.93 | 2023 | |
| Madrigal Pharmaceuticals | $20.63 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2024 | |
| Verity Pharmaceuticals INC. | $16.85 | 2025 | Tlando |
| Amphastar Pharmaceuticals, INC. | $14.51 | 2023 | Baqsimi |
| Pfizer INC. | $13.92 | 2025 | |
| Mannkind Corporation | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhilasha Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.